Recruiting Intergroup trials not coordinated by the EORTC

Protocol
Title
Coordinating Group
08111A randomised, open-label phase III trial evaluating the addition of denosumab to standard first-line anticancer treatment in advanced NSCLC

Study Coordinator:

Sarah Danson, Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital, Sheffield

European Thoracic Oncology Platform
1201A prospective randomised phase III study of androgen deprivation therapy (+/- docetaxel) with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.

Study Coordinator:

Dominik Berthold, Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne

UNICANCER
1219A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic radiosensitizer nimorazole (Nimoral), using a 15 gene signature for hypoxia in the treatment of squamous cell carcinoma of the head and neck

Study Coordinator:

Vincent Gregoire, Cliniques Universitaires Saint-Luc, Brussels

Jens Overgaard, Aarhus University Hospital, Aarhus

Danish Head & Neck Cancer Group
1308Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial (The ROAM trial) / EORTC 1308

Study Coordinator:

Matthias Preusser, Medical University Vienna - General Hospital AKH, Vienna

Damien Weber, Paul Scherrer Institute - Center for Proton Therapy (CPT), Villigen

The Walton Centre NHS Foundation Trust
1321A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST).

Study Coordinator:

Jean-Yves Blay, Centre Leon Berard, Lyon

Australasian Gastro-Intestinal Trials Group
1324A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

Study Coordinator:

Fatima Cardoso, Champalimaud Cancer Center, Lisboa

Breast International Group
1402International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing’s Sarcoma Family of Tumours – Euro Ewing 2012

Study Coordinator:

Andre Johan (Hans) Gelderblom, Leiden University Medical Centre, Leiden

Bernadette Brennan, CMUH-Royal Manchester Children's Hospital, Manchester

University of Birmingham
1403International Randomised Controlled Trial of Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma

Study Coordinator:

Uta Dirksen, Universitaetsklinikum Muenster, Zentralklinikum , Muenster

Bernadette Brennan, CMUH-Royal Manchester Children's Hospital, Manchester

Martin McCabe, The Christie NHS Foundation Trust, Manchester

University of Birmingham
1407A Randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by High-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors

Study Coordinator:

Thomas Powles, Barts Health NHS Trust - St. Bartholomew'S Hospital, London

Susanne Harnisch, Koordinierungszentrum für Klinische Studien (KKS) am Medizinische Fakultät der Philipps-Universität Marburg, Marburg

Alliance
1408Aiming to Understand the MOlecular Aberrations in Metastatic Breast Cancer

Study Coordinator:

Martine Piccart, Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels

Fatima Cardoso, Champalimaud Cancer Center, Lisboa

Breast International Group
1502A phase II study of Palbociclib plus Fulvestrant vs Fulvestrant plus Placebo for pretreated patients with ER+/HER2- metastatic Breast Cancer; Palbociclib in molecularly characterized ER-Positive/HER2 negative metastatic Breast Study: the PYTHIA study

Study Coordinator:

Francois Duhoux, Cliniques Universitaires Saint-Luc, Brussels

International Breast Cancer Study Group
1513PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast Cancer

Study Coordinator:

Fatima Cardoso, Champalimaud Cancer Center, Lisboa

Austrian Breast and Colorectal Cancer Study Group
22055Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement - LUNG-ART

Study Coordinator:

Cecile Le Pechoux, Gustave Roussy, Villejuif

Institut Gustave Roussy
22114Trial of preoperative therapy for gastric and esophagogastric junction adenocarcinoma. A randomized phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.

Study Coordinator:

Karin Haustermans, U.Z. Leuven - Campus Gasthuisberg, Leuven

Florian Lordick, Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden , Leipzig

Trans-Tasman Radiation Oncology Group Inc
22114Trial of preoperative therapy for gastric and esophagogastric junction adenocarcinoma. A randomized phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.

Study Coordinator:

Karin Haustermans, U.Z. Leuven - Campus Gasthuisberg, Leuven

Florian Lordick, Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden , Leipzig

Australasian Gastro-Intestinal Trials Group
55102A phase III Trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer.

Study Coordinator:

Frederic Amant, U.Z. Leuven - Campus Gasthuisberg, Leuven

Mansoor Raza Mirza, Rigshospitalet, Copenhagen

Danish Gynaecological Cancer Group
58111International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010. A randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group

Study Coordinator:

Pierre Rohrlich, CHU de Nice - Hopital De L'Archet, Nice

Charite Universitaetsmedizin Berlin